Document Detail


Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
MedLine Citation:
PMID:  23211038     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background: Fingolimod and natalizumab have the same European Union licence for the treatment of relapsing multiple sclerosis, and are considered by the Committee for Medicinal Products for Human Use (CHMP) to have broadly similar efficacy. Objective: A cost-minimization analysis was performed to compare differences in treatment costs between fingolimod and natalizumab from a societal perspective in Sweden. Methods: This analysis included costs associated with initiating and following treatment (physician visits and monitoring), continuing therapy (drugs and administration), and lost patient productivity and leisure time. Unit costs (in Swedish krona [SEK]) were based on regional data (median prices for physician visits and monitoring sessions). Natalizumab infusion costs were obtained from the national cost-per-patient database. Drug costs for both therapies were 15,651 SEK/28 days. Results: After 3 years, fingolimod use was associated with savings of 124,823 SEK/patient compared with natalizumab (total cost/patient: 566,718 SEK versus 691,542 SEK). Cost savings with fingolimod were 40,402 SEK/patient after 1 year and 301,730 SEK/patient after 10 years. Treatment with natalizumab was 18% more expensive than fingolimod therapy after 1 year and 23% more expensive after 10 years. Limitations: Based on the CHMP assessment, it was assumed that fingolimod and natalizumab have similar efficacy. The analysis was conducted for Sweden, and caution is needed in extrapolating the results to other countries. Conclusion: Fingolimod is cost saving compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
Authors:
Niklas Bergvall; Magnus Tambour; Freddie Henriksson; Sten Fredrikson
Related Documents :
18193968 - Early treatment to correct class iii relations with or without face masks.
18632838 - A randomized controlled study of early headgear treatment on occlusal stability--a 13 y...
9702638 - The use of kinesiography to assess mandibular rest positions following corrective ortho...
15747808 - Nasal airway changes due to rapid maxillary expansion timing.
12461338 - Treatment of isolated sphenoid sinus inflammatory disease by endoscopic sphenoidotomy w...
16447238 - Risk genotypes in folate-dependent enzymes and their association with methotrexate-rela...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-4
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to en...
Next Document:  Aptamer-conjugated multifunctional nanoflowers as a platform for targeting, capture, and detection i...